Fully funded by 
Content independently selected
Postmarketing study shows comparable outcomes for patients older than 70 years.
Roughly 7 in 10 patients responded to therapy.
Limited dose may have limited outcomes.
More than 7 in 10 patients achieved complete remission.
Interventions needed to help survivors readapt.
Findings may assist in prognostic assessment/treatment decisions.
Potential value for patients with insufficient response to comparators.
Data from a real-world Spanish study.
Incidence expected to increase as the population ages.
More serious AEs in patients receiving eltrombopag.
Digestive, urinary, and hematologic cancers are implicated.
77% reduction in risk for disease progression or death.
Low pre-HCT MRD positivity, high-level 5-year OS.
Population study shows doubled risk for NHL, particularly DLBCL.
SLCO1B1 allele variants may exacerbate reduced MTX clearance.
Grade 4 neutropenia associated with one-third increase in mortality risk.
Age was the only independent predictor for early death.
